Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Director | May 04, 2026 | May 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
WEST PHARMACEUTICAL SERVICES INC
Report date May 04, 2026 · Filed May 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,495.55 |
Reported balance
After 2026-05-04 transaction · row 1
1 source rowRow 1 · 2026-05-04 · Grant · Acquired 791 · Balance 46,495.55 F1: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ORASURE TECHNOLOGIES INC
Report date March 31, 2018 · Filed April 03, 2018
Section 16 reporting ended · disclosed 2018-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 660,861 |
Reported balance
After 2018-03-31 transaction · row 1
1 source rowRow 1 · 2018-03-31 · Tax withholding · Disposed 56,078 · Balance 660,861 F1: Withholding of shares to pay the tax liability associated with vesting of restricted shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Withholding of shares to pay the tax liability associated with vesting of restricted shares.
TYME TECHNOLOGIES, INC.
Report date September 16, 2022 · Filed September 16, 2022
Section 16 reporting ended · disclosed 2022-09-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-09-16 transaction · row 1
1 source rowRow 1 · 2022-09-16 · Disposition to issuer · Disposed 110,000 · Balance 0 F1: Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 4,820 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares. |
| Director Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $2.71 · Expires 2028-10-01 | Direct | 0 |
Reported balance
After 2022-09-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-09-16 · Disposition to issuer · Disposed 45,833 · Balance 0 F2: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,008 shares of Syros common stock for $61.84 per share, after giving effect to the Reverse Split. |
| Director Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $2.71 · Expires 2028-10-01 | Direct | 0 |
Reported balance
After 2022-09-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-09-16 · Disposition to issuer · Disposed 100,000 · Balance 0 F3: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 4,382 shares of Syros common stock for $61.84 per share, after giving effect to the Reverse Split. |
| Director Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2029-08-22 | Direct | 0 |
Reported balance
After 2022-09-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-09-16 · Disposition to issuer · Disposed 50,000 · Balance 0 F4: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split. |
| Director Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2030-08-19 | Direct | 0 |
Reported balance
After 2022-09-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-09-16 · Disposition to issuer · Disposed 65,000 · Balance 0 F5: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split. |
| Director Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2031-08-23 | Direct | 0 |
Reported balance
After 2022-09-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-09-16 · Disposition to issuer · Disposed 88,000 · Balance 0 F6: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split. |
| Director Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2032-08-23 | Direct | 0 |
Reported balance
After 2022-09-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-09-16 · Disposition to issuer · Disposed 88,000 · Balance 0 F7: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 4,820 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.
F2: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,008 shares of Syros common stock for $61.84 per share, after giving effect to the Reverse Split.
F3: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 4,382 shares of Syros common stock for $61.84 per share, after giving effect to the Reverse Split.
F4: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split.
F5: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split.
F6: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split.
F7: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2017 Filed May 11, 2017 21:29 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionCommon stock | 195,833 | $5.71 | $1,119,166.01 |
DisclosureSEC source: 0001209784-17-000038 · edgar.xml · nonDerivative · entry 2 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 977,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2017 Filed May 11, 2017 21:29 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionCommon stock | 13,967 | $7.05 | $98,397.52 |
DisclosureSEC source: 0001209784-17-000038 · edgar.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 782,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2017 Filed May 9, 2017 22:48 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionNonqualified stock options · Derivative | 167,916 | $0.00 Strike: $7.05 | $0.00 |
DisclosureSEC source: 0001209784-17-000034 · edgar.xml · derivative · entry 9 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,967 Underlying: Common stock · 167,916 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Nonqualified stock options granted on February 1, 2013 vesting and exercisable over a four-year period, with one-fourth of the options vesting on the first anniversary date of the grant and the remainder vesting ratably on a monthly basis, over the remaining 36 months. Read SEC document |
| May 08, 2017 Filed May 9, 2017 22:48 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionNonqualified stock options · Derivative | 79,738 | $0.00 Strike: $6.63 | $0.00 |
DisclosureSEC source: 0001209784-17-000034 · edgar.xml · derivative · entry 8 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 79,738 shares Expires 2021-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Nonqualified stock options granted on February 1, 2011 vesting and exercisable over a four-year period, with one-fourth of the options vesting on the first anniversary date of the grant and the remainder vesting ratably on a monthly basis, over the remaining 36 months. Read SEC document |
| May 08, 2017 Filed May 9, 2017 22:48 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | SaleCommon stock | 167,916 | $15.09 | $2,533,852.44 |
DisclosureSEC source: 0001209784-17-000034 · edgar.xml · nonDerivative · entry 6 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 768,058 Read SEC document |
| May 08, 2017 Filed May 9, 2017 22:48 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionCommon stock | 167,916 | $7.05 | $1,182,968.22 |
DisclosureSEC source: 0001209784-17-000034 · edgar.xml · nonDerivative · entry 5 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 935,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2017 Filed May 9, 2017 22:48 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | SaleCommon stock | 79,738 | $15.09 | $1,203,246.42 |
DisclosureSEC source: 0001209784-17-000034 · edgar.xml · nonDerivative · entry 4 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 768,058 Read SEC document |
| May 08, 2017 Filed May 9, 2017 22:48 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionCommon stock | 79,738 | $6.63 | $528,264.25 |
DisclosureSEC source: 0001209784-17-000034 · edgar.xml · nonDerivative · entry 3 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2017 Filed May 9, 2017 22:48 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionNonqualified stock options · Derivative | 113,562 | $0.00 Strike: $6.63 | $0.00 |
DisclosureSEC source: 0001209784-17-000034 · edgar.xml · derivative · entry 7 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,738 Underlying: Common stock · 113,562 shares Expires 2021-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Nonqualified stock options granted on February 1, 2011 vesting and exercisable over a four-year period, with one-fourth of the options vesting on the first anniversary date of the grant and the remainder vesting ratably on a monthly basis, over the remaining 36 months. Read SEC document |
| May 05, 2017 Filed May 9, 2017 22:48 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | SaleCommon stock | 113,562 | $15.06 | $1,710,243.72 |
DisclosureSEC source: 0001209784-17-000034 · edgar.xml · nonDerivative · entry 2 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 768,058 Read SEC document |
| May 05, 2017 Filed May 9, 2017 22:48 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionCommon stock | 113,562 | $6.63 | $752,348.25 |
DisclosureSEC source: 0001209784-17-000034 · edgar.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2017 Filed May 3, 2017 18:57 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-001690 · primarydocument.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,717.439 F1 · price: These shares of restricted stock units will vest in full after 12 months and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 19:17 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 306.035 | $81.69 | $25,000.00 |
DisclosureSEC source: 0001562180-17-001424 · primarydocument.xml · derivative · entry 2 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,142.9022 Underlying: Common Stock · 306.035 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 21:39 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionNonqualified stock option · Derivative | 102,365 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001209784-17-000020 · edgar.xml · derivative · entry 6 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 102,365 shares Expires 2020-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Nonqualified stock options granted on January 25, 2010 vesting and exercisable over a four-year period, with one-fourth of the options vesting on the first anniversary date of the grant and the remainder vesting ratably on a monthly basis, over the remaining 36 months. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 21:39 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionNonqualified stock option · Derivative | 90,990 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001209784-17-000020 · edgar.xml · derivative · entry 5 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 90,990 shares Expires 2019-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Nonqualified stock options granted on January 23, 2009 vesting and exercisable over a four-year period, with one-fourth of the options vesting on the first anniversary date of the grant and the remainder vesting ratably on a monthly basis, over the remaining 36 months. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 21:39 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | SaleCommon stock | 102,365 | $10.27 | $1,051,186.19 |
DisclosureSEC source: 0001209784-17-000020 · edgar.xml · nonDerivative · entry 4 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 768,058 F3 · kind: Sale pursuant to a predetermined sales plan, entered into on August 22, 2016, under Rule 10b5-1 of the Securities and Exchange Act of 1934. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 21:39 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | SaleCommon stock | 90,990 | $10.14 | $923,084.45 |
DisclosureSEC source: 0001209784-17-000020 · edgar.xml · nonDerivative · entry 3 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 870,423 F3 · kind: Sale pursuant to a predetermined sales plan, entered into on August 22, 2016, under Rule 10b5-1 of the Securities and Exchange Act of 1934. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 21:39 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionCommon stock | 102,365 | $5.19 | $531,274.35 |
DisclosureSEC source: 0001209784-17-000020 · edgar.xml · nonDerivative · entry 2 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 961,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 21:39 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionCommon stock | 90,990 | $2.81 | $255,226.95 |
DisclosureSEC source: 0001209784-17-000020 · edgar.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 859,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 22:11 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Tax withholdingCommon stock | 19,208 | $8.84 | $169,798.72 |
DisclosureSEC source: 0001209784-17-000016 · edgar.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 768,058 F1 · kind: Withholding of shares to pay the tax liability associated with vesting of restricted shares. Read SEC document |
| February 01, 2017 Filed Feb 2, 2017 23:20 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | GrantCommon stock | 77,695 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209784-17-000008 · edgar.xml · nonDerivative · entry 3 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 787,266 F2 · kind: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, with one-third of the grant vesting on February 1, 2018, February 1, 2019, and February 1, 2020. Vesting shall cease upon voluntary termination of employment. F2 · price: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, with one-third of the grant vesting on February 1, 2018, February 1, 2019, and February 1, 2020. Vesting shall cease upon voluntary termination of employment. Read SEC document |
| February 01, 2017 Filed Feb 2, 2017 23:20 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Tax withholdingCommon stock | 15,837 | $8.87 | $140,474.19 |
DisclosureSEC source: 0001209784-17-000008 · edgar.xml · nonDerivative · entry 2 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 709,571 F1 · kind: Withholding of shares to pay the tax liability associated with vesting of restricted shares. Read SEC document |
| January 20, 2017 Filed Feb 2, 2017 23:20 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | GiftCommon stock | 6,490 | $8.61 | $55,846.45 |
DisclosureSEC source: 0001209784-17-000008 · edgar.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 725,408 Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 19:57 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 293.4272 | $85.20 | $25,000.00 |
DisclosureSEC source: 0001562180-17-000146 · primarydocument.xml · derivative · entry 2 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,820.2423 Underlying: Common Stock · 293.4272 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 02:07 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionNon-qualified stock options · Derivative | 56,250 | $0.00 Strike: $8.06 | $0.00 |
DisclosureSEC source: 0001209784-16-000059 · edgar.xml · derivative · entry 6 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 56,250 shares Expires 2018-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Nonqualified stock options granted on February 1, 2008 vesting and exercisable over a four-year period, with one-fourth of the options vesting on the first anniversary date of the grant and the remainder vesting ratably on a monthly basis, over the remaining 36 months. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 02:07 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionNon-qualified stock options · Derivative | 15,216 | $0.00 Strike: $8.28 | $0.00 |
DisclosureSEC source: 0001209784-16-000059 · edgar.xml · derivative · entry 5 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 15,216 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Nonqualified stock options granted on February 1, 2007 vesting and exercisable over a four-year period, with one-fourth of the options vesting on the first anniversary date of the grant and the remainder vesting ratably on a monthly basis, over the remaining 36 months. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 02:07 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | SaleCommon stock | 56,250 | $9.08 | $510,750.00 |
DisclosureSEC source: 0001209784-16-000059 · edgar.xml · nonDerivative · entry 4 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731,898 F1 · kind: Sale pursuant to a predetermined sales plan, entered into on August 22, 2016 under Rule 10b5-1 of the Securities and Exchange Act of 1934. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 02:07 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | SaleCommon stock | 15,216 | $9.02 | $137,248.32 |
DisclosureSEC source: 0001209784-16-000059 · edgar.xml · nonDerivative · entry 3 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 788,148 F1 · kind: Sale pursuant to a predetermined sales plan, entered into on August 22, 2016 under Rule 10b5-1 of the Securities and Exchange Act of 1934. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 02:07 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionCommon stock | 56,250 | $8.06 | $453,093.75 |
DisclosureSEC source: 0001209784-16-000059 · edgar.xml · nonDerivative · entry 2 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 803,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 02:07 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionCommon stock | 15,216 | $8.28 | $125,912.40 |
DisclosureSEC source: 0001209784-16-000059 · edgar.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 747,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2016 Filed Dec 12, 2016 17:46 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionNon-qualified stock options · Derivative | 23,891 | $0.00 Strike: $8.28 | $0.00 |
DisclosureSEC source: 0001209784-16-000058 · edgar.xml · derivative · entry 3 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,216 Underlying: Common stock · 23,891 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Nonqualified stock options granted on February 1, 2007 vesting and exercisable over a four-year period, with one-fourth of the options vesting on the first anniversary date of the grant and the remainder vesting ratably on a monthly basis, over the remaining 36 months. Read SEC document |
| December 09, 2016 Filed Dec 12, 2016 17:46 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | OtherCommon stock | 23,891 | $9.01 | $215,257.91 |
DisclosureSEC source: 0001209784-16-000058 · edgar.xml · nonDerivative · entry 2 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731,898 F1 · kind: Sale pursuant to a predetermined sales plan, entered into on August 22, 2016, under Rule 10b5-1 of the Securities and Exchange Act of 1934. Read SEC document |
| December 09, 2016 Filed Dec 12, 2016 17:46 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionCommon stock | 23,891 | $8.28 | $197,698.03 |
DisclosureSEC source: 0001209784-16-000058 · edgar.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 755,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2016 Filed Nov 29, 2016 00:29 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionNon-qualified stock options · Derivative | 5,893 | $0.00 Strike: $8.28 | $0.00 |
DisclosureSEC source: 0001209784-16-000057 · edgar.xml · derivative · entry 6 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,107 Underlying: Common stock · 5,893 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Nonqualified stock options granted on February 1, 2007 vesting and exercisable over a four-year period, with one-fourth of the options vesting on the first anniversary date of the grant and the remainder vesting ratably on a monthly basis, over the remaining 36 months. Read SEC document |
| November 23, 2016 Filed Nov 29, 2016 00:29 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | SaleCommon stock | 142 | $9.01 | $1,279.42 |
DisclosureSEC source: 0001209784-16-000057 · edgar.xml · nonDerivative · entry 5 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731,898 F1 · kind: Sale pursuant to a predetermined sales plan, entered into on August 22, 2016, under Rule 10b5-1 of the Securities and Exchange Act of 1934. Read SEC document |
| November 23, 2016 Filed Nov 29, 2016 00:29 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | SaleCommon stock | 5,751 | $9.03 | $51,931.53 |
DisclosureSEC source: 0001209784-16-000057 · edgar.xml · nonDerivative · entry 4 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 732,040 F1 · kind: Sale pursuant to a predetermined sales plan, entered into on August 22, 2016, under Rule 10b5-1 of the Securities and Exchange Act of 1934. Read SEC document |
| November 23, 2016 Filed Nov 29, 2016 00:29 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionCommon stock | 142 | $8.28 | $1,175.05 |
DisclosureSEC source: 0001209784-16-000057 · edgar.xml · nonDerivative · entry 3 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 737,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2016 Filed Nov 29, 2016 00:29 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Exercise / conversionCommon stock | 5,751 | $8.28 | $47,589.53 |
DisclosureSEC source: 0001209784-16-000057 · edgar.xml · nonDerivative · entry 2 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 737,649 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2016 Filed Nov 29, 2016 00:29 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | SaleCommon stock | 25,000 | $9.02 | $225,500.00 |
DisclosureSEC source: 0001209784-16-000057 · edgar.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731,898 F1 · kind: Sale pursuant to a predetermined sales plan, entered into on August 22, 2016, under Rule 10b5-1 of the Securities and Exchange Act of 1934. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 19:07 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 337.2909 | $74.12 | $25,000.00 |
DisclosureSEC source: 0001225208-16-039975 · doc4.xml · derivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,493.4605 Underlying: Common Stock · 337.2909 shares Expires not disclosed F1 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 21:40 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | SaleCommon stock | 25,000 | $8.22 | $205,525.00 |
DisclosureSEC source: 0001209784-16-000052 · edgar.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756,898 F1 · kind: Sale pursuant to a predetermined sales plan, entered into on August 22, 2016, under Rule 10b5-1 of the Securities and Exchange Act of 1934. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.